Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195

Analysts Adjust Price Targets for Moderna Following Q3 Results

Several financial institutions, including Goldman Sachs, Piper Sandler, RBC, and Jefferies, adjusted their price targets for Moderna following the company's third-quarter earnings report.

Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305

Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?

Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.

Goldman Sachs Adjusts Price Target on Moderna

Goldman Sachs has revised its price target for Moderna, increasing it to $195 from the previous $137.

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

Moderna Stuns Wall Street With Surprise Profit, Raises Outlook

Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.